{"id":1260,"date":"2015-07-22T14:28:22","date_gmt":"2015-07-22T18:28:22","guid":{"rendered":"http:\/\/blogs.cooperhealth.org\/sjmedicalreport\/?p=1260"},"modified":"2015-07-22T14:29:48","modified_gmt":"2015-07-22T18:29:48","slug":"coopers-structural-heart-disease-program-this-is-a-totally-different-world-of-structural-heart-disease-treatment","status":"publish","type":"post","link":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/2015\/07\/22\/coopers-structural-heart-disease-program-this-is-a-totally-different-world-of-structural-heart-disease-treatment\/","title":{"rendered":"Cooper\u2019s Structural Heart Disease Program: \u201cThis Is a Totally Different  World of Structural Heart Disease Treatment\u201d"},"content":{"rendered":"<p>Advances in percutaneous and minimally invasive surgical techniques have revolutionized the way structural heart disease can be treated today \u2013 and Cooper is in the forefront of the revolution.<\/p>\n<p>\u201cThis is a totally different world of structural heart disease treatment than existed even five years ago,\u201d says Janah Aji, MD, Co-Director of Cooper\u2019s Structural Heart Disease Program. \u201cThere are revolutionary new approaches for treating aortic stenosis and for preventing embolic disease in atrial fibrillation. We\u2019re closing septal defects and paravalvular leaks. And the algorithm for treating mitral valve regurgitation is going to change dramatically in the next few years.<\/p>\n<p>\u201cFor almost every structural heart problem that exists, we either have technology already available or under investigation here at Cooper,\u201d he adds. \u201cOur capabilities are unrivaled in southern New Jersey, and for the most exciting and progressive new technologies we are one of only two or three medical centers that can make them available between New York and Washington, DC.\u201d<\/p>\n<p>These capabilities include transcatheter aortic valve replacement (TAVR), in which a bioprosthetic valve is inserted percutaneously and implanted in the orifice of the native aortic valve. FDA-approved in the past year and a half for patients who are at high risk or ineligible for open heart surgery, TAVR improves quality of life and extends survival in a previously untreatable patient population. Although a number of hospitals now have TAVR, Cooper has done more procedures than any hospital in New Jersey and is one of only two sites in the Delaware Valley with the next generation, smaller, easier to deploy heart valve.<\/p>\n<p>\u201cFor an 85-year-old with aortic stenosis who is now totally disabled, we have an option for getting them out of a wheelchair and giving both a longer as well as a better quality of life,\u201d according to Sajjad A. Sabir, MD, Co-Director of Cooper\u2019s<br \/>\nStructural Heart Program.<\/p>\n<p>In fact, Cooper not only has performed more TAVR<br \/>\nprocedures than any other New Jersey facility but is also ranked<br \/>\n11th in volume among 220 commercial TAVR sites in the U.S. Moreover, Cooper is the only hospital in the state participating in the PARTNER II clinical trial, making the next generation of TAVR technology available and extending its application to aortic stenosis patients at moderate risk for surgery.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advances in percutaneous and minimally invasive surgical techniques have revolutionized the way structural heart disease can be treated today \u2013 and Cooper is in the forefront of the revolution. \u201cThis is a totally different world of structural heart disease treatment than existed even five years ago,\u201d says Janah Aji, MD, Co-Director of Cooper\u2019s Structural Heart &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/2015\/07\/22\/coopers-structural-heart-disease-program-this-is-a-totally-different-world-of-structural-heart-disease-treatment\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-dzarnosky","4":"post-1260","6":"format-standard","7":"category-news-updates"},"_links":{"self":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/comments?post=1260"}],"version-history":[{"count":1,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1260\/revisions"}],"predecessor-version":[{"id":1338,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1260\/revisions\/1338"}],"wp:attachment":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/media?parent=1260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/categories?post=1260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/tags?post=1260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}